Objective: To evaluate serum prolyl-hydroxylase, an enzyme reflecting hepatic fibrogenic activity, in healthy subjects and patients with various liver diseases. Design: Serum prolyl-hydroxylase was evaluated in patients with varying degrees of liver damage and was related to standard liver function tests. Methods: One hundred and thirty-one patients were studied, 25 with steatosis or chronic persistent hepatitis, 37 with chronic active hepatitis, 35 with Child’s class A cirrhosis and 34 with Child’s class B cirrhosis. Serum prolyl-hydroxylase was measured by means of an immune enzymatic method. Results: Serum prolyl-hydroxylase was found to be (mean ± SD) 62 ±15ng/ml in 43 healthy subjects, 70 ± 20 ng/ml in patients with steatosis or chronic persistent hepatitis, 174 ± 86 ng/ml in patients with chronic active hepatitis (P <0.01 compared with healthy and other disease groups), 124 ± 62 ng/ml (P <0.01 compared with healthy subjects) in patients with Child’s class A cirrhosis and 94 ± 55 ng/ml in those with Child’s class B cirrhosis. Serum prolyl-hydroxylase was related to liver function tests in multiple regression analysis (131 patients; r = 0.643, P <0.001) confirming the hepatic source of this enzyme in chronic liver disease. Conclusion: The higher values found in chronic active hepatitis and in the early stages of cirrhosis suggest that fibrogenesis, evaluated by means of serum prolyl-hydroxylase levels, is likely to be a reaction to inflammatory damage of the liver. On the basis of these results, serum prolyl-hydroxylase seems to be a possible marker for identifying fibrogenic activity in patients with chronic liver disease and could be a possible target for the evaluation of antifibrogenic drugs.
|Number of pages||5|
|Journal||European Journal of Gastroenterology and Hepatology|
|Publication status||Published - 1993|
- Chronic active hepatitis
- Liver function tests
ASJC Scopus subject areas